← Back to all trials
Active Not Recruiting
NCT04947501
A Study of N9 Chemotherapy in Children With Neuroblastoma
Conditions: Neuroblastoma, Pediatric Cancer
Sex: All
Ages: 1 Year – 19 Years
Healthy volunteers: No
Phase: EARLY_PHASE1
Enrollment: 26
Sponsor: Memorial Sloan Kettering Cancer Center
Location: Memorial Sloan Kettering Cancer Center New York New York
Summary
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV).
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of NB as defined by histopathology (confirmed by the MSK Department of Pathology), BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
* HR-NB, defined as MYCN-amplified stage 2/3/4/4S at any age and stage 4 in patients \>18 months old.
* No more than one prior cycle of chemotherapy.
* Age \
Source: ClinicalTrials.gov (NCT04947501). StuddyBuddy aggregates publicly available trial information.
